FNDC4 reduces hepatocyte inflammatory cell death via AMPKα in metabolic dysfunction-associated steatotic liver disease
Gabriela Neira(Instituto de Salud Carlos III), Amaia Rodrı́guez(Instituto de Salud Carlos III), Gema Frühbeck(Clinica Universidad de Navarra), Camilo Silva(Instituto de Salud Carlos III), Sara Becerril(Instituto de Salud Carlos III), Javier Escalada(Clinica Universidad de Navarra), Javier Gómez‐Ambrosi(Instituto de Salud Carlos III), Rafael Moncada(Instituto de Salud Carlos III), Víctor Valentí(Instituto de Salud Carlos III), Inmaculada Colina(Clinica Universidad de Navarra), Victoria Catalán(Instituto de Salud Carlos III)
Cited by 16
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
|Diabetes Care|2016|969
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary
|Diabetologia|2024|150
Ghrelin reduces TNF-α-induced human hepatocyte apoptosis, autophagy and pyroptosis: role in obesity-associated NAFLD
|The Journal of Clinical Endocrinology & Metabolism|2018|110